<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35977919</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Strengthened surveillance revealed a rapid disappearance of the poliovirus serotype 2 vaccine strain in Madagascar after its removal from the oral polio vaccine.</ArticleTitle><Pagination><StartPage>5877</StartPage><EndPage>5884</EndPage><MedlinePgn>5877-5884</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.28071</ELocationID><Abstract><AbstractText>To assess circulation of the Sabin 2 poliovirus vaccine strain in Madagascar after its withdrawal from the oral polio vaccine in April 2016, a reinforced poliovirus surveillance was implemented in three regions of Madagascar from January 2016 to December 2017. Environmental samples and stool specimens from healthy children were screened using the Global Polio Laboratory Network algorithm to detect the presence of polioviruses. Detected polioviruses were molecularly typed and their genomes fully sequenced. Polioviruses were detected during all but 4 months of the study period. All isolates were related to the vaccine strains and no wild poliovirus was detected. The majority of isolates belong to the serotype 3. The last detection of Sabin 2 occurred in July 2016, 3 months after its withdrawal. No vaccine-derived poliovirus of any serotype was observed during the study. Only few poliovirus isolates contained sequences from non-polio origin. The genetic characterization of all the poliovirus isolates did not identify isolates that were highly divergent compared to the vaccine strains. This observation is in favor of a good vaccine coverage that efficiently prevented long-lasting transmission chains between unvaccinated persons. This study underlines that high commitment in the fight against polioviruses can succeed in stopping their circulation even in countries where poor sanitation remains a hurdle.</AbstractText><CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Razafindratsimandresy</LastName><ForeName>Richter</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Madagascar, Antananarivo, Madagascar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joffret</LastName><ForeName>Marie-Line</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raharinantoanina</LastName><ForeName>Jonhson</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Madagascar, Antananarivo, Madagascar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polston</LastName><ForeName>Patsy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andriamamonjy</LastName><ForeName>Nelson S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Madagascar, Antananarivo, Madagascar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razanajatovo</LastName><ForeName>Iony Manitra</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Madagascar, Antananarivo, Madagascar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Ousmane M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Polio Eradication, Director General's Office, World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delpeyroux</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institut Pasteur, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Héraud</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Madagascar, Antananarivo, Madagascar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bessaud</LastName><ForeName>Maël</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6758-9591</Identifier><AffiliationInfo><Affiliation>Institut Pasteur, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008270" MajorTopicYN="N" Type="Geographic">Madagascar</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Madagascar</Keyword><Keyword MajorTopicYN="N">poliomyelitis</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">vaccine-derived poliovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>22</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35977919</ArticleId><ArticleId IdType="doi">10.1002/jmv.28071</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>O'Grady M, Bruner PJ. Polio Vaccine. In: StatPearls [Internet]. StatPearls Publishing; 2021. http://www.ncbi.nlm.nih.gov/books/NBK526039/</Citation></Reference><Reference><Citation>Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(suppl 1):S283-S293.</Citation></Reference><Reference><Citation>Ramirez Gonzalez A, Farrell M, Menning L, et al. Implementing the synchronized global switch from trivalent to bivalent oral polio vaccines-lessons learned from the global perspective. J Infect Dis. 2017;216(suppl_1):S183-S192.</Citation></Reference><Reference><Citation>Joffret ML, Jégouic S, Bessaud M, et al. Common and diverse features of cocirculating type 2 and 3 recombinant vaccine-derived polioviruses isolated from patients with poliomyelitis and healthy children. J Infect Dis. 2012;205(9):1363-1373.</Citation></Reference><Reference><Citation>Rakoto-Andrianarivelo M, Gumede N, Jegouic S, et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J Infect Dis. 2008;197(10):1427-1435.</Citation></Reference><Reference><Citation>Razafindratsimandresy R, Joffret ML, Rabemanantsoa S, Andriamamonjy S, Heraud JM, Delpeyroux F. Reemergence of recombinant vaccine-derived polioviruses in healthy children, Madagascar. Emerg Infect Dis. 2013;19(6):1008-1010.</Citation></Reference><Reference><Citation>Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis. 2003;9(7):885-887.</Citation></Reference><Reference><Citation>Nimpa MM, Razafiarivao NR, Robinson A, et al. Efforts towards polio eradication in Madagascar: 1997 to 2017. J Immunol Sci. 2021;Spec Issue(2):1102.</Citation></Reference><Reference><Citation>Anonymous. WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use [Internet]. Disponible sur https://polioeradication.org/wp-content/uploads/2016/12/GAPIII_2014.pdf</Citation></Reference><Reference><Citation>Anonymous. Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses [Internet]. Disponible sur. https://polioeradication.org/wp-content/uploads/2016/07/PIM-guidance-20190122-EN.pdf</Citation></Reference><Reference><Citation>Jorba J, Diop OM, Iber J, Sutter RW, Wassilak SG, Burns CC. Update on vaccine-derived polioviruses-worldwide, January 2015−May 2016. MMWR Morb Mortal Wkly Rep. 2016;65(30):763-769.</Citation></Reference><Reference><Citation>World Health Organization. Guidelines for environmental surveillance of poliovirus circulation [Internet]. World Health Organization; 2003 [cité 26 janv 2021]. Disponible sur. https://apps.who.int/iris/handle/10665/67854</Citation></Reference><Reference><Citation>World Heath Organization. Polio laboratory manual [Internet]. World Health Organization; 2004 [cité 26 janv 2021]. Disponible sur. https://apps.who.int/iris/handle/10665/68762</Citation></Reference><Reference><Citation>World Health Organization. New algorithm for poliovirus isolation Supplement 1. pdf. 2017.</Citation></Reference><Reference><Citation>Kilpatrick DR, Yang CF, Ching K, et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J Clin Microbiol. 2009;47(6):1939-1941.</Citation></Reference><Reference><Citation>Bessaud M, Sadeuh-Mba SA, Joffret ML, et al. Whole genome sequencing of enterovirus species C isolates by high-throughput sequencing: development of generic primers. Front Microbiol. 2016;7:1294.</Citation></Reference><Reference><Citation>Joffret ML, Polston PM, Razafindratsimandresy R, Bessaud M, Heraud JM, Delpeyroux F. Whole genome sequencing of enteroviruses species A to D by high-throughput sequencing: application for viral mixtures. Front Microbiol. 2018;9:2339.</Citation></Reference><Reference><Citation>Laassri M, Lottenbach K, Belshe R, Rennels M, Plotkin S, Chumakov K. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J Infect Dis. 2006;193(10):1344-1349.</Citation></Reference><Reference><Citation>Huang QS, Greening G, Baker MG, et al. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet. 2005;366(9483):394-396.</Citation></Reference><Reference><Citation>Huyen DTT, Mach O, Thanh Trung N, et al. Rapid disappearance of poliovirus type 2 (PV2) immunity in young children following withdrawal of oral PV2-containing vaccine in Vietnam. J Infect Dis. 2019;220(3):386-391.</Citation></Reference><Reference><Citation>Mueller JE, Bessaud M, Huang QS, et al. Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina. Appl Environ Microbiol. 2009;75(5):1395-1401.</Citation></Reference><Reference><Citation>Blake IM, Pons-Salort M, Molodecky NA, et al. Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine. N Engl J Med. 2018;379(9):834-845.</Citation></Reference><Reference><Citation>Razafindratsimandresy R, Mach O, Heraud JM, et al. Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar. Heliyon. 2018;4(3):e00563.</Citation></Reference><Reference><Citation>Muslin C, Mac Kain A, Bessaud M, Blondel B, Delpeyroux F. Recombination in enteroviruses, a multi-step modular evolutionary process. Viruses. 2019;11(9):859.</Citation></Reference><Reference><Citation>Alleman MM, Jorba J, Greene SA, et al. Update on vaccine-derived poliovirus outbreaks-worldwide, July 2019 to February 2020. MMWR Morb Mortal Wkly Rep. 2020;69(16):489-495.</Citation></Reference><Reference><Citation>Joffret ML, Doté JW, Gumede N, Vignuzzi M, Bessaud M, Gouandjika-Vasilache I. Vaccine-derived polioviruses, Central African Republic, 2019. Emerg Infect Dis. 2021;27(2):620-623.</Citation></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of outbreak response strategies for 2019−2029: impacts of using a novel type 2 oral poliovirus vaccine strain. Risk Anal. 2021;41(2):329-348.</Citation></Reference><Reference><Citation>Alleman MM. Update on vaccine-derived poliovirus outbreaks-worldwide, January 2020 to June 2021. MMWR Morb Mortal Wkly Rep, 70(49):1691-1699. https://www.cdc.gov/mmwr/volumes/70/wr/mm7049a1.htm</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>